---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-034143"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:52:48.685483+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vir Bio Q2 net loss narrows to $138M; initiates restructuring cutting 25% of workforce

## Summary
- Net loss of $138.4M ($1.02/sh) vs $194.8M ($1.45/sh) in Q2 2023; cash and investments $1.43B, down $78M in quarter.
- Strategic restructuring reduces workforce by ~140 employees (25%); phases out flu, COVID-19, and T-cell viral vector programs.
- Expects $11–13M in restructuring charges, ~$50M annual workforce cost savings from 2025, and ~$50M program savings through 2025.
- Lowers full-year 2024 GAAP operating expense guidance to $580–610M, excluding Sanofi transaction impact.
- Signed exclusive worldwide license with Sanofi for clinical-stage T-cell engagers; CMO Mark Eisner appointed June 2024.

## SEC filing metadata
- accession: 0001628280-24-034143
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000162828024034143/0001628280-24-034143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000162828024034143/vir-20240729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-034143
- JSON: https://secwatch.observer/filing/0001628280-24-034143.json
- Plain text: https://secwatch.observer/filing/0001628280-24-034143.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.